The GOG Foundation, Inc. and GOG Partners welcome gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to listen to the Evolving Evidence and Treatment Strategies in Platinum Resistant Ovarian Cancer: From Biology to Bedside symposium podcast that was presented at the FSGO 2026 Annual Meeting in Long Boat Key, Florida a on Friday, June 12, 2026.
Platinum‑resistant ovarian cancer (PROC) remains a major therapeutic challenge due to modest survival outcomes and frequent treatment resistance. This CME session delivers a science‑forward, methodologic update designed to help clinicians interpret evolving evidence and educate the audience on thoughtful practice-based approach. Faculty will cover the current treatment landscape and survival benchmarks; mechanisms of resistance that inform next‑generation strategies; a masterclass in interpreting Phase 3 data (design, endpoints, and external validity); and equity and access considerations including biomarker testing logistics, clinical trial access, and shared decision‑making. Through a moderated panel, attendees will contextualize new evidence, anticipate how pending regulatory decisions may impact care, and identify research implications.
This educational activity is supported by an independent medical education grant from Corcept Therapeutics